BH vs TSLA

The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of 4/9, indicating borderline stability, and the absence of an Altman Z-Score prevents a full distress risk assessment. Despite strong recent price performance (+110.4% over 1Y), the stock trades at an extremely high P/E of 217.27 versus negative Forward P/E, signaling earnings deterioration. Profitability metrics are concerning, with a mere 0.54% net margin and 0.35% ROE, well below sector averages. While the balance sheet shows a healthy current ratio and low Price/Book of 0.50, these are overshadowed by unsustainable valuation and weak earnings momentum.

Tesla's deterministic health is stable with a Piotroski F-Score of 4/9, but its valuation is fundamentally disconnected from current performance. The Graham Number ($22.85) and Intrinsic Value ($7.42) indicate extreme overvaluation relative to the current price of $343.25. With negative YoY revenue growth (-3.10%) and a collapse in earnings growth (-60.60%), the P/E ratio of 323.82 is unsustainable. Technical trends and insider activity are both strongly bearish, suggesting a significant correction is likely.